ClinicalTrials.gg
CompletedNCT00562497Updated Jan 19, 2022

Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)

A Phase 3 interventional study of Prochymal® and Placebo in Graft Versus Host Disease, sponsored by Mesoblast, Inc.. Completed at 53 sites in 3 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-01-19.

Sponsored by Mesoblast, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2009, 17 years 4 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Dec 2021.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Enrollment
17th of 389
192 · median 30
Started
2008
with 22 others
Phase 3
40 of 454
2 open now
Registered
147th of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 17th largest by enrollment of the 389 interventional ones that give a count, is one of 23 that started in 2008, is one of 40 in phase 3, and was the 147th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

This is a Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of Prochymal® versus placebo in combination with corticosteroids as initial therapy for acute GVHD. Corticosteroids have been the primary therapy for patients with previously untreated acute GVHD and the historical published data define an expected 35% complete response (CR) at Day +28 using this therapy.

Read the detailed description

Participants will be treated with a total of 6 infusions of investigational agent during the first 4 weeks of the study. The first infusion of the investigational product (IP) will be administered within 72 hours of the start of systemic corticosteroid therapy. Four infusions will be administered during the first two weeks (twice weekly), then two infusions administered during the next two weeks (once weekly). Participants assigned to the active treatment group will receive Prochymal®. Participants assigned to the non active treatment group will receive placebo (excipient, less cells). It is recommended that all participants receive all six infusions. The discontinuation of investigational agent is allowed for GVHD worsening with subsequent need for salvage therapy. All infusions must be given at least 3 days apart.

Participants will be evaluated for efficacy and safety until death, withdrawal or 90 study days after randomization, whichever occurs first. Study will be unblinded and data analyzed at Day 90 post 1st infusion (Day 0) following final participant enrollment. Participants will be followed for safety for 12 months post 1st infusion (Day 0).

03

Conditions studied

  • Graft Versus Host Disease

Browse trials for

Keywords

  • Acute GVHD
  • Acute Graft Versus Host Disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 18 years to 70 years of age, inclusive
  • Participants must have received an hematopoietic stem cell transplant using either bone marrow, peripheral blood stem cells or cord blood or administered a donor leukocyte infusion.
  • Participants must have newly diagnosed Grades B-D acute . confirmation of GVHD is strongly recommended but not required. Randomization should not be delayed awaiting biopsy or pathology results.
  • Participants must be randomized and treated with (1-2 mg/kg/d methylprednisolone, or equivalent) and Prochymal®/placebo within 72 hours of onset of acute GVHD.
  • Participants must have adequate renal function as defined by: Calculated of >30 mL/min using the Cockcroft-Gault equation
  • Participants who are women of , must be non-pregnant, not breast-feeding, and use adequate . Male participants must use adequate contraception
  • Participant must have a minimum Performance Level of at least 30 at the time of study entry
  • Participant (or legal representative where appropriate) must be capable of providing written .

Exclusion criteria

Exclusion Criteria:

  • Participant has been previously treated with systemic therapy for acute
  • Participant has any underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would interfere with the evaluation of the participant including uncontrolled infection, heart failure, pulmonary hypertension, etc.
  • Participants may not receive any other agents (not approved by the FDA for any indication) concurrently during study participation or within 30 days of randomization.
  • Participant has a known allergy to bovine or porcine products or dimethyl sulfoxide (DMSO)
  • Participant has received a transplant for a solid tumor disease.
  • Participant requires more than 2 liters/min of oxygen to maintain stable oxygen saturation (Sa02) greater than or equal to 92%
  • Participant requires a renal dopamine dose greater than 1-3 mcg/kg/min to maintain renal blood flow associated with renal failure and improved urinary output.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
192 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive 6 infusions of placebo-matching Prochymal® intravenously (IV) during the first 4 weeks of the study. The first infusion will be administered within 72 hours of the start of systemic corticosteroid therapy. Participants will receive 4 infusions during the first 2 weeks (twice weekly at least 3 days apart), followed by 2 infusions administered once weekly over the subsequent 2 weeks up to Day 28.

    Other: Placebo · Other: Corticosteroid

  • Active comparator
    Prochymal® 2x10^6 hMSC/kg

    Participants will receive 6 infusions of Prochymal® 2x10\^6 human mesenchymal stem cells (hMSC)/kg IV during the first 4 weeks of the study. The first infusion will be administered within 72 hours of the start of systemic corticosteroid therapy. Participants will receive 4 infusions during the first 2 weeks (twice weekly at least 3 days apart), followed by 2 infusions administered once weekly over the subsequent 2 weeks up to Day 28.

    Drug: Prochymal® · Other: Corticosteroid

Interventions

  • Prochymal® intravenous infusion.

    Also known as: Remestemcel-L

  • OtherPlacebo

    Placebo-matching Prochymal® intravenous infusion.

  • OtherCorticosteroid

    Administration will be intravenously as prescribed by the caregiver.

    Also known as: Methylprednisolone, Prednisone

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Treatment Success

    Treatment was considered a success if all of the following conditions were met: Achieved induction of a complete response (CR) within 28 days after first infusion; CR followed by 28 days maintenance of a clinically meaningful response defined as the response that did not require an increase in corticosteroid dose (methylprednisolone doses \>2 milligram/kilogram/day \[mg/kg/d\] or prednisone doses \>2.5 mg/kg/d) for more than 7 consecutive days; Did not require second line/escalation therapy through Study Day 56; and survived 90 study days.

    Time frame: 90 Days

Secondary outcomes

  1. Percentage of Participants with Overall Response

    Overall Response was defined as participants who achieved complete response or partial response (CR+PR).

    Time frame: Day 90

  2. Percentage of Participants with Induction of a 2-grade decrease in (Graft Versus Host Disease) GVHD by Study Day 28 with maintenance of a 2-grade decrease in GVHD through Study Day 56

    Time frame: Up to Day 56

  3. Percentage of Participants with Induction of CR lasting for greater than or equal to 14 Days

    Time frame: Day 14

  4. Percentage of Participants with Induction of a CR after Study Day 28 and clinically managed with steroids with second line/escalation therapy through Study Day 56

    Time frame: Up to Day 56

  5. Percentage of Participants with Induction of PR during the first 28 days

    Time frame: Up to Day 28

  6. Time to achieve CR

    Time frame: Up to Day 90

  7. Number of CR per organ

    Time frame: Up to Day 90

  8. Total corticosteroid dose administered

    Time frame: Up to Day 90

  9. Number of corticosteroid-related complications

    Corticosteroid-related complications included hyperglycemia requiring insulin, corticosteroid myopathy and psychosis.

    Time frame: Up to Day 90

  10. Number of Infectious complications

    Infectious complications included viral, fungal or bacterial complications.

    Time frame: Up to Day 90

  11. Number of Days of Hospitalization

    Time frame: Up to Day 90

  12. Average Daily Corticosteroid Dose

    Time frame: Up to Day 90

07

Study locations

53 sites
  • University of Alabama Birmingham (UAB) Hospital
    Birmingham, Alabama 35249, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • University of California Medical Center
    San Francisco, California 94143, United States
  • Rocky Mountain Cancer Center
    Denver, Colorado 80218, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Northside Hospital
    Atlanta, Georgia 30342, United States
  • Northwestern Center for Clinical Research
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Chicago Hospitals
    Chicago, Illinois 60637, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Indiana University Cancer Center
    Indianapolis, Indiana 46202, United States
  • St. Francis Cancer Center
    Indianapolis, Indiana 46237, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Tufts New England Medical Center
    Boston, Massachusetts 02111, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Mayo Medical Center
    Rochester, Minnesota 55905, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Kansas City Cancer Center
    Lee's Summit, Missouri 64064, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • New York Presbyterian Hospital
    New York, New York 10065, United States
  • University of North Carolina Hospitals
    Chapel Hill, North Carolina 27514, United States
  • Duke University Health System
    Durham, North Carolina 27705, United States
  • Wake Forest University School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • Jewish Hospital
    Cincinnati, Ohio 45236, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Penn State Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Abramson Cancer Center, University of Pennsylvania Health System
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Western Pennsylvania Hospital
    Pittsburgh, Pennsylvania 15224, United States
  • Oncology Hematology Association
    Pittsburgh, Pennsylvania 15232, United States
  • University of Pittsburgh Cancer Centers
    Pittsburgh, Pennsylvania 15232, United States
  • Medical University of South Carolina(MUSC)
    Charleston, South Carolina 29425, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Texas Transplant Institute
    San Antonio, Texas 78229, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Royal Perth Hospital
    Perth, Western Australia 6001, Australia
  • St. Vincent's Hospital
    Darlinghurst, NSW 2010, Australia
  • Royal Brisbane Hospital
    Herston, QLD 4029, Australia
  • Peter Lougheed Centre
    Calgary, Alberta T1Y 6J4, Canada
  • Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2008 to primary completion in Jul 2009, 17 months.

Of 31 phase 3 interventional studies under Graft vs Host Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 48. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2007
First posted
Nov 22, 2007
StartActual
Jan 31, 2008
Primary completionActual
Jul 14, 2009
CompletionActual
May 20, 2010
Results delay requested
Dec 3, 2021
Last update
Jan 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00562497
Lead sponsor
Mesoblast, Inc.
Responsible party
Sponsor
First posted
Nov 22, 2007
Start date
Jan 31, 2008
Primary completion
Jul 14, 2009
Completion
May 20, 2010
Last update
Jan 19, 2022

Study contacts

Christopher James, PA
study director · Mesoblast, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remestemcel-l

Start the discussion